Onco Actu du 27 mai 2020

	1. BIOLOGIE
Lymph Node Metastases Form Through a Wider Evolutionary Bottleneck than Distant Metastases [Mass. General Hospital] Reconstructing the evolutionary histories of dozens of primary colorectal cancers and their metastases, the team showed that lymph node metastases are a genetically highly diverse group. Their pronounced heterogeneity indicates that they can be seeded by many different primary tumor sub-lineages.
	1.1 BIOLOGIE - GÉNOME
Colorectal Cancer Study Reveals Tumor Mutation, Immune Microenvironment Relationships [Genome Web] An international research team has uncovered apparent ties between tumor mutational patterns and immune features in the surrounding microenvironment in dozens of colorectal cancer (CRC) patients from Korea and Belgium.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
Exclusive: Research finds concerning drop in U.S. colorectal cancer screenings and surgeries [Reuters] Research by the health data firm Komodo Health and exclusively shared with Reuters found new colorectal cancer diagnoses declined more than 32%, while the number of performed colonoscopies and biopsies fell by nearly 90% from mid-March to mid-April, compared with the same period last year.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Anti-malarial drug shows promise for brain cancer treatment [Massey Cancer Center] Innovative screening strategies for Fli-1 inhibitors identified lumefantrine as a prospective agent that could bind to Fli-1, inactivate it and thereby suppress expression of important genes regulating growth, survival and oncogenicity (ability to cause tumors) of glioblastoma multiforme.
	5.10 TRAITEMENTS - ESSAIS
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma [NCI] In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. The findings were published May 26, 2020, in the Journal of Clinical Oncology.
	5.12.6 IMMUNOTHÉRAPIES - AMM
Bristol Myers Squibb's Opdivo, Yervoy score another lung cancer OK, this time alongside chemo [Fierce Pharma] The go-ahead comes just 11 days after the agency cleared Opdivo and Yervoy for use sans chemo in PD-L1-positive patients.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer [BMS] Approval marks sixth indication for Opdivo + Yervoy-based combinations across five types of cancer.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
Immunotherapy for triple-negative breast cancer approved for NHS in England [Cancer Research UK] The final decision comes in response to the company that developed atezolizumab submitting new data analysis and an amended price, after the drug was initially rejected by NICE in October last year.
	5.5 ASCO
ASCO press program highlights COVID-19 outcomes in lung cancer patients [VUMC] “The data on the first 200 patients was primarily from France, Italy and Spain,” Horn said. “The outcomes were pretty shocking. There was 35% mortality in patients with a thoracic malignancy. Almost three-quarters of the patients required hospital admission.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
‘Forced to retract completely into ourselves,’ a mother and son confront cancer in the age of Covid-19 [STAT] Amy and Landen, two generations fighting cancer, are united by something else: They are going through the most frightening and painful moments of their lives without the family warmth and support that was standard practice at the nation’s medical centers — until Covid-19.